Immunotherapy has transformed the treatment of many cancers, and bladder cancer is no exception. Unlike traditional chemotherapy, which attacks cancer cells directly, immunotherapy works by enabling the immune system to recognize and destroy cancer cells. In bladder cancer, immunotherapy has shown particular promise, especially for patients with advanced disease who have not responded to other treatments. The rise of immunotherapy is one of the most significant trends shaping the Bladder Cancer Market.

Checkpoint inhibitors are the most prominent class of immunotherapies used in bladder cancer. These drugs block proteins that cancer cells use to evade the immune system, allowing immune cells to attack the tumor. Several checkpoint inhibitors are approved for bladder cancer, including drugs targeting PD-1 and PD-L1. They are used in various settings, including first-line treatment for patients who cannot receive chemotherapy and as second-line treatment after chemotherapy failure. Bacillus Calmette-Guérin, or BCG, is another form of immunotherapy used for non-muscle invasive bladder cancer and has been a standard treatment for decades. These therapies have improved outcomes for many patients, and research continues to expand their applications.

Challenges remain. Not all patients respond to immunotherapy, and identifying which patients will benefit is an active area of research. Biomarkers, such as PD-L1 expression, can help guide treatment decisions, but they are not perfect. Side effects, including autoimmune reactions, can occur and require management. Cost and access are also considerations. Despite these challenges, immunotherapy has become a cornerstone of bladder cancer treatment, and its role is likely to grow as new agents and combinations are developed.

People Also Ask

How does immunotherapy work in bladder cancer?
It enables the immune system to recognize and attack cancer cells, often by blocking proteins that cancer cells use to evade immune detection.

What is BCG therapy?
It is an immunotherapy used for non-muscle invasive bladder cancer, instilled directly into the bladder to stimulate an immune response against cancer cells.

Tags: #BladderCancer #Immunotherapy #CheckpointInhibitors #BCG #Oncology #CancerTreatment